Pelthos Therapeutics Inc. (PTHS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

46/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

66

Undervalued

Momentum

50

Neutral

Sentiment

61

Bullish

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Scott Plesha
Listed since: Feb 16, 2024
Employees: 92

Market position

Day range

Current $25.51

$25.00$28.4731

52-week range

Current $25.51

$18.19$37.50

Open: $26.41
Previous close: $26.66
Volume: 20.8K; 0.5× average
Average volume: 41.63K; Average daily volume
Market cap: 88.66M USD
Beta: 3.13; Market reference 1
50-day average: $27.381; -6.83% below average
200-day average: $25.8806; -1.43% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 75.1M USD
EV / EBITDA: -1.65×
Earnings yield: -74.31%
Free cash flow yield: -38.92%

Profitability & efficiency

Return on equity: -111.41%
Return on assets: -33.22%
Return on invested capital: -26.38%

Financial health

Current ratio: 2.03×

Financial statements

Income trends

Operating income

−32.43M USD-328.32%

Net income

−43.32M USD-444.53%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	16.8M USD	—	—	—	—
Cost of goods sold	9.37M USD	—	—	—	—
Gross profit	7.43M USD	—	—	—	—
Research and development	1.23M USD	1.18M USD	2.58M USD	391.73K USD	209.05K USD
Selling, general, and administrative	37.08M USD	6.39M USD	4.28M USD	1.93M USD	629.95K USD
Operating expenses	39.86M USD	7.57M USD	6.86M USD	2.32M USD	839K USD
Interest income	5K USD	—	—	—	—
Interest expense	3.01M USD	786.39K USD	518.51K USD	140.43K USD	253 USD
Depreciation and amortization	2.29M USD	—	—	—	—
Operating income	−32.43M USD	−7.57M USD	−6.86M USD	−2.32M USD	−839K USD
Net income	−43.32M USD	−7.96M USD	−7.38M USD	−2.46M USD	−595.39K USD